Display options
Cite
Harada K, Ferdous T, Harada T, et al. Gimeracil enhances the antitumor effect of cisplatin in oral squamous cell carcinoma cells . Oncol Lett. 2017;14(3):3349-3356doi: 10.3892/ol.2017.6602.
Harada, K., Ferdous, T., Harada, T., Takenawa, T., & Ueyama, Y. (2017). Gimeracil enhances the antitumor effect of cisplatin in oral squamous cell carcinoma cells . Oncology letters, 14(3), 3349-3356. https://doi.org/10.3892/ol.2017.6602
Harada, Koji, et al. "Gimeracil enhances the antitumor effect of cisplatin in oral squamous cell carcinoma cells ." Oncology letters vol. 14,3 (2017): 3349-3356. doi: https://doi.org/10.3892/ol.2017.6602
Harada K, Ferdous T, Harada T, Takenawa T, Ueyama Y. Gimeracil enhances the antitumor effect of cisplatin in oral squamous cell carcinoma cells . Oncol Lett. 2017 Sep;14(3):3349-3356. doi: 10.3892/ol.2017.6602. Epub 2017 Jul 18. PMID: 28927087; PMCID: PMC5587992.
Copy Download .nbib Format: NLM
Share it on

Oncol Lett. 2017 Sep;14(3):3349-3356. doi: 10.3892/ol.2017.6602. Epub 2017 Jul 18.

Gimeracil enhances the antitumor effect of cisplatin in oral squamous cell carcinoma cells .

Oncology letters

Koji Harada, Tarannum Ferdous, Toyoko Harada, Takanori Takenawa, Yoshiya Ueyama

Affiliations

  1. Department of Oral and Maxillofacial Surgery, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755-8505, Japan.

PMID: 28927087 PMCID: PMC5587992 DOI: 10.3892/ol.2017.6602

Abstract

Gimeracil or 5-chloro-2,4-dihydroxypyridine (CDHP) enhances the antitumor effects of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase (DPD), which is involved in the degradation of 5-FU. CDHP, as part of a combination therapy, was also reported to exert a radiosensitizing effect. Therefore, CDHP may have underlying mechanisms of action other than DPD inhibition. The focus of the present study was to investigate the antitumor effects of CDHP and cisplatin (CDDP) combination treatment

Keywords: antitumor effect; cisplatin; combined therapy; gimeracil; oral squamous cell carcinoma

References

  1. Jpn J Cancer Res. 1987 Jul;78(7):748-55 - PubMed
  2. Gan To Kagaku Ryoho. 2001 Oct;28(10):1381-90 - PubMed
  3. Cancer Sci. 2011 Sep;102(9):1712-6 - PubMed
  4. Clin Cancer Res. 1999 Sep;5(9):2620-8 - PubMed
  5. Gan To Kagaku Ryoho. 2010 Oct;37(10 ):1987-90 - PubMed
  6. Radiother Oncol. 2010 Aug;96(2):259-66 - PubMed
  7. Gan To Kagaku Ryoho. 2006 Jun;33 Suppl 1:150-4 - PubMed
  8. Cancer Treat Rep. 1982 Mar;66(3):471-4 - PubMed
  9. Cancer Chemother Rep. 1975 May-Jun;59(3):589-98 - PubMed
  10. J Cancer Res Clin Oncol. 2007 Nov;133(11):841-6 - PubMed
  11. Proc Natl Acad Sci U S A. 1986 Dec;83(23):8923-5 - PubMed
  12. Anticancer Drugs. 1996 Jul;7(5):548-57 - PubMed
  13. Cancer Res. 1996 Jun 1;56(11):2602-6 - PubMed
  14. Gan To Kagaku Ryoho. 2013 Mar;40(3):323-5 - PubMed
  15. Gan To Kagaku Ryoho. 2009 Nov;36(11):1829-31 - PubMed
  16. Strahlenther Onkol. 2012 Mar;188(3):255-61 - PubMed
  17. Anticancer Drugs. 2008 Jan;19(1):85-90 - PubMed
  18. Jpn J Clin Oncol. 2010 Mar;40(3):214-21 - PubMed
  19. Anticancer Res. 2016 Nov;36(11):5923-5930 - PubMed

Publication Types